People · Operator
Named in public records as an officer, director or promoter · active 2010–2026 · Healthtech, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Imperative Care, Inc. | — | Healthtech | Series D+ | $584.7M | $713.0M | 2026 |
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2011 |
| Intersect ENT, Inc. | — | Other Health Care | Series B | $85.7M | $462.2M | 2010 |
| Insite Vision Inc | — | Biotechnology | Series B | $24.6M | $94.5M | 2011 |
| Asuragen Inc | — | Biotechnology | Series A | $12.5M | $271.1M | 2011 |
Evan S. Melrose at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Evan S. Melrose on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher D Earl | 2 | 3 |
| Matthew M Winkler | 2 | 2 |
| Peter Barrett | 1 | 18 |
| FARHAD KHOSRAVI | 1 | 14 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Tara Butler | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Chau Khuong | 1 | 9 |
| Frederic H. Moll | 1 | 8 |
| Henry Chen | 1 | 7 |
| Dana G. Mead, Jr. | 1 | 7 |
| Elaine Jones | 1 | 6 |
| Lewis Geffen | 1 | 6 |
| Amar Sawhney | 1 | 6 |
| Daniel Geffken | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Paul Miller | 1 | 5 |
| Hank Plain | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.